First-in-class drug may prevent organ failure and death associated with sepsis
最近審查：14.06.2024
所有iLive內容都經過醫學審查或事實檢查，以確保盡可能多的事實準確性。
我們有嚴格的採購指南，只鏈接到信譽良好的媒體網站，學術研究機構，並儘可能與醫學同行評審的研究相關聯。 請注意括號中的數字（[1]，[2]等）是這些研究的可點擊鏈接。
如果您認為我們的任何內容不准確，已過時或有疑問，請選擇它並按Ctrl + Enter。
A new drug may prevent organ failure and death associated with sepsis by restoring the health of a patient's blood vessels.
Researchers from the University of Queensland and Queensland Children's Hospital have successfully tested a new class of drug in mice.
Dr Mark Coulthard, from the University of Queensland's paediatric intensive care unit and hospital, said preclinical results using human blood samples also looked promising.
The cause of organ failure in patients with sepsis is that the endothelial cells lining the blood vessels become permeable, leading to abnormal fluid shifts and eventually cutting off the blood supply.
We identified markers of vascular injury in children admitted to hospital with fever and suspected infection, and the protein signalling pathways associated with this in cells.
The drug we developed targets the interactions of these pathways to restore vascular endothelial cell function," said Dr Mark Coulthard.
Professor Trent Woodruff, from the University of Queensland's School of Biomedical Sciences, said the new approach addresses the root cause of organ failure, whereas previous unsuccessful attempts had largely focused on the immune response.
"Sepsis has been called a 'graveyard for pharmaceutical companies' because despite significant resources and more than 100 clinical trials, there is still no effective treatment that modifies the host response," said Professor Woodruff.
"A drug that targets the vascular endothelium could potentially could reduce the damage caused by sepsis, organ damage and death."
Dr Coulthard said the researchers were encouraged by the results of the preclinical trials.
"We tested our drug in blood samples from 91 children admitted to hospital with fever and suspected infection, and saw changes in biomarkers similar to those in our mouse studies," he said.
"This suggests that the drug may be effective in humans as well.
Further research is needed, including examining the drug in other animal models and its effectiveness in clinical trials."
The study was published in the journal Science Translational Medicine.